250 listed companies released performance reports, and many pharmaceutical companies doubled their net profit

Recently, it has been a period of intensive disclosure of the performance reports of major listed companies
.
The data shows that as of now, a total of 250 listed companies have released relevant data on their 2021 performance reports, including a number of pharmaceutical and biological companies.
Overall, pharmaceutical and biological companies have a higher reporting rate, including Wantai Bio, Dongyang Sunshine, and Zuoli Pharmaceutical.
The net profit of many companies such as the industry doubled
.
Rejing Bio: Net profit increased by more than 1800% year-on-year According to the 2021 performance report released by Rejing Bio, the company's operating income during the reporting period was approximately 5.
372 billion yuan, an increase of 946.
14% year-on-year; the corresponding attributable net profit achieved was approximately 21.
93 100 million yuan, a year-on-year increase of 1856.
81%
.
Regarding the reason for the increase in net profit, Rejing Bio said that mainly due to the impact of the epidemic, the antigen self-test products developed by the company have successively passed the self-test registration/filing of major economies such as Germany and the European Union, and have been quickly applied to local anti-epidemic needs.
This is caused by a substantial increase in foreign trade orders; Zhifei Bio, a vaccine company with the highest net profit in 2021, said that its performance growth is mainly due to the continuous and steady increase in the sales of its own products and agency products
.
Zhifei Bio: Net profit increased by 208.
88% year-on-year According to the recent performance report disclosed by Zhifei Bio, after preliminary accounting, the company will achieve operating income of 30.
637 billion yuan in 2021, a year-on-year increase of 101.
68%; operating profit of 11.
986 billion yuan, a year-on-year increase of 207.
73%
.
The reason for the increase in performance, Zhifei Bio said, is mainly because the company has increased investment in research and development to bring forth new ideas, the sales of independent products and agency products have continued to increase steadily, and the company's main business income, net profit and other important financial indicators are higher than the same period last year.
magnitude increase
.
It is worth mentioning that Zhifei Bio also announced recently that the company's controlling shareholder Jiang Rensheng reduced his holdings of 28.
78 million unrestricted tradable shares of the company through a block transaction and transferred them to the company's employee stock ownership plan
.
Wantai Bio: Net profit increased by 198.
59% year-on-year Recently, the 2021 annual report disclosed by Wantai Bio showed that the company achieved revenue of 5.
750 billion yuan, a year-on-year increase of 144.
25%; net profit attributable to the parent was 2.
021 billion yuan, a year-on-year increase of 198.
59%
.
As for the reasons for the growth in performance, Wantai Bio said that it was mainly due to the increase in revenue of bivalent cervical cancer vaccines, reagents and active raw materials, etc.
, the demand for overseas testing increased significantly, and the company's raw material sales and overseas testing reagent export revenue achieved rapid growth
.
Haier Bio: Net profit increased by 114.
81% Haier Bio will achieve revenue of 2.
126 billion yuan in 2021, a year-on-year increase of 51.
63%
.
In the same period, the net profit was 818 million yuan, a year-on-year increase of 114.
81%
.
The company explained that with the continuous deepening of the Internet of Things strategy, the company continued to invest in research and development to promote innovative iterations of technology and product solutions, accelerated the expansion of channel networks and expanded its competitive advantages in the global market, and achieved double-high growth in the Internet of Things solution business and traditional business
.
HEC: Net profit increased by 106.
91% year-on-year On March 10, HEC released the 2021 annual performance report, achieving a total operating income of 12.
798 billion yuan, an increase of 23.
40% over the same period of the previous year; the net profit attributable to shareholders of the listed company was 860 million yuan, An increase of 106.
91% over the same period last year
.
It is understood that the company's performance growth is mainly due to its grasp of market opportunities.
During the reporting period, the company actively reduced costs and increased efficiency through internal deepening reforms, and enhanced the efficiency of production, sales and research
.
Zuoli Pharmaceutical: Net profit increased by 101.
28% year-on-year Zuoli Pharmaceutical released the 2021 annual performance report on the evening of March 9.
During the reporting period, the company achieved operating income of 1.
457 billion yuan, an increase of 33.
60% over the same period last year; net profit of 179 million Yuan, an increase of 101.
28% over the same period of the previous year
.
The company said that its performance has been stable and improving in recent years, mainly due to the rapid growth in the operating income of its main products Wuling Capsules, Bailing Tablets and Lingze Tablets, and the continuous enhancement of the "hematopoietic" function; in addition, with the company's profitability With the improvement of the company's funds, the company's funds are more abundant, the loan scale has been reduced, and the burden of financial expenses has been further reduced
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.